ReviewFrontiers in pediatrics2018
Immunotherapy and Asthma in Children.
Review in Frontiers in pediatrics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 41 citations in OpenAlex.
- Characterisation ofJournal of fungi (Basel, Switzerland) · 2025Article
- Studying of anti-inflammatory and antioxidant effects of tectorigenin in ovalbumin-induced asthma mice models.The clinical respiratory journal · 2024Article
- Clinical and experimental treatment of allergic asthma with an emphasis on allergen immunotherapy and its mechanisms.Clinical and experimental immunology · 2023Article
- Allergic asthma: An indication for allergen immunotherapy.Allergologie select · 2023Review
- Monitoring disease activity of pollen allergies: What crowdsourced data are telling us.The World Allergy Organization journal · 2022Article
- Asthma: From Phenotypes to Personalized Medicine.Journal of personalized medicine · 2022Article
- Allergic Asthma in the Era of Personalized Medicine.Journal of personalized medicine · 2022Review
- Allergen Management in Children with Type 2-High Asthma.Journal of asthma and allergy · 2022Review
- Morning Versus Evening Dosing of Sublingual Immunotherapy in Allergic Asthma: A Prospective Study.Frontiers in pediatrics · 2022Article
- Allergen Immunotherapy in Pediatric Asthma: A Pragmatic Point of View.Children (Basel, Switzerland) · 2020Review
- Allergic Endotypes and Phenotypes of Asthma.The journal of allergy and clinical immunology. In practice · 2020Article
- Two Sides of the Same Coin?-Treatment of Chronic Asthma in Children and Adults.Frontiers in pediatrics · 2019Review
- Novel therapeutic targets for allergic airway disease in children.Drugs in context · 2019Review
- Immunomodulation in Pediatric Asthma.Frontiers in pediatrics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergen immunotherapy (AIT) is still the only disease-modifying treatment strategy for IgE-mediated allergic diseases, with consolidated evidence both in adults and children. AIT is effective in determining clinical improvement of allergic rhinitis and asthma, such as reduced symptoms, medication use, and improvement of quality of life, with a long-lasting effect after cessation of treatment. Results from recent clinical studies have implemented the evidence of effectiveness and safety of allergen immunotherapy for the treatment of allergic asthma, so that the current asthma guidelines now recommend sublingual immunotherapy as an add-on therapy for asthma in adults and adolescents with house dust mite allergy, allergic rhinitis, and exacerbations despite low-to-moderate dose ICS, with forced expiratory volume in 1 second more than 70% predicted. AIT may also reduce the risk of progression from allergic rhinitis to asthma in children and prevent the onset of new sensitizations, thus representing a potentially preventive method of treatment. The aim of this review is to present an updated overview of the clinical indications of AIT, with particular reference to pediatric asthma, of the mechanisms of clinical and immunological tolerance to allergens, and of the potential biomarkers predicting clinical response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.